FDA Brief

Warning letters Drugs

FDA warning letter to

Bell International Laboratories, Inc.

High riskIssued Feb 15, 2024Posted Mar 5, 2024Division of Pharmaceutical Quality Operations III

Bell International Laboratories, an OTC drugmaker, was cited for manufacturing rule violations including missing glycerin DEG/EG testing and inadequate quality oversight.

What happened

FDA inspected Bell International Laboratories' drug manufacturing facility in Eagan, Minnesota, from September 11 to 19, 2023. FDA found an inadequate quality unit, incomplete investigations and missing or incomplete batch and testing records, failure to test each glycerin lot for diethylene glycol and ethylene glycol, and an unvalidated pH adjustment step. FDA also said the company's response to the Form FDA 483 inspection observations was inadequate.

What FDA found

  1. The company's quality unit did not adequately oversee OTC drug manufacturing, including investigations of non-conformances and complaints and control and retention of records.

    21 CFR 211.22(a) and (d)
  2. The company failed to perform adequate identity testing on each component lot, including a USP limit test for diethylene glycol (DEG) and ethylene glycol (EG) on all glycerin lots before use.

    21 CFR 211.84(d)(1)
  3. The company did not validate its manufacturing process; for at least two lots it adjusted pH using an unvalidated process and said it followed cosmetic regulations for topical drugs.

    21 CFR 211.100(a)
  4. The company failed to ensure adequate investigations into non-conformances.

    21 CFR 211.192
  5. The company failed to ensure adequate investigations into complaints.

    21 CFR 211.198(a)
  6. The company failed to maintain complete and accurate batch and testing records, including missing records and out-of-specification investigations.

    21 CFR 211.188

What FDA wants

FDA tells Bell to correct the violations promptly and respond in writing within 15 working days with plans, assessments, and corrective actions; it also asks for DEG/EG test results within 30 calendar days. FDA recommends a qualified CGMP consultant.

Who should pay attention

  • brands and retailers selling OTC drug products made by Bell
  • companies buying glycerin-containing drug products from contract manufacturers
  • quality teams at drug manufacturers using high-risk components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk